Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan
Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan
复制标题
DOI：
10.1093/jnci/89.23.1789
复制
发表时间：
1997-12-03
期刊：
影响因子：
--
通讯作者：
Wilding, G
中科院分区：
文献类型：
--
作者：
Bailey, HH;Ripple, G;Wilding, G
背景:长期以来，细胞内谷胱甘肽的增加与肿瘤细胞对各种细胞毒性药物的耐药性有关，谷胱甘肽生物合成抑制剂L-S， r -丁硫氨酸亚砜胺（BSO）已被证明可以增强化疗药物的体外和体内细胞毒性。我们进行了一项BSO与抗癌药物melphalan联合使用的I期研究，以确定该组合的安全性/耐受性，并确定BSO是否能在临床上产生所需的谷胱甘肽耗散的生化终点(
Background: Increased intracellular glutathione has long been associated with tumor cell resistance to various cytotoxic agents, An inhibitor of glutathione biosynthesis, L-S,R-buthionine sulfoximine (BSO), has been shown to enhance the cytotoxicity of chemotherapeutic agents in vitro and in vivo, We performed a phase I study of BSO administered with the anticancer drug melphalan to determine the combination's safety/tolerability and to determine clinically whether BSO produced the desired biochemical end point of glutathione depletion (